Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.


Biological Chemistry

Protein Levels Vary With Fate Of Treated Cancer Cells

Study provides insight into how different proteins are produced and move around inside living cells exposed to drugs

by Stuart A. Borman
November 24, 2008 | APPEARED IN VOLUME 86, ISSUE 47

Not much is known about the way different proteins are produced and move around in living cells exposed to drugs. But a research team has now used a proteomics approach to study such processes in cancer cells exposed to the chemotherapy drug camptothecin (Science, DOI: 10.1126/science.1160165). Researchers could pursue the strategy to identify proteins associated with specific cell properties, such as enhanced drug resistance, and in their efforts to design more effective medications. Molecular cell biology graduate students Ariel A. Cohen, Naama Geva-Zatorsky, and Eran Eden of Weizmann Institute of Science, in Rehovot, Israel, and coworkers used time-lapse fluorescence microscopy to monitor the levels and locations of close to 1,000 different fluorescently tagged proteins in camptothecin-exposed human cancer cells. They found that levels of two proteins, the RNA helicase DDX5 and the replication factor RFC1, increase in cells that survive and decrease in those that die. They confirmed DDX5's effect on cell fate by showing that RNA-interference-induced reduction of protein levels boosted cell death after exposure to camptothecin.



This article has been sent to the following recipient:

Leave A Comment

*Required to comment